Replimune Group, Inc.
NasdaqGS REPL
Replimune Group, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -3.79
-
Replimune Group, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.40 on May 29, 2024, which is 63.15% above the current Price to Earnings Ratio (P/E).
-
Replimune Group, Inc. 52-week low Price to Earnings Ratio (P/E) is -5.39 on November 22, 2024, which is -42.33% below the current Price to Earnings Ratio (P/E).
-
Replimune Group, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.99.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Sushil Patel Ph.D. |
| IPO Date | July 20, 2018 |
| Location | United States |
| Headquarters | 500 Unicorn Park Drive |
| Employees | 331 |
| Sector | Health Care |
| Industries | |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Past 5 years
USD 23.67
USD 39.01
USD 12.60
USD 364.70
USD 1.94
USD 9.12
USD 7.26
USD 35.62
USD 36.67
USD 5.64
USD 2.47
USD 131.57
USD 12.48
USD 72.39
StockViz Staff
January 15, 2025
Any question? Send us an email